1. Interleukin-4 suppresses plasminogen activator inhibitor-2 formation in stimulated human monocytes.
- Author
-
Hamilton JA, Whitty GA, Last K, Royston AK, Hart PH, and Burgess DR
- Subjects
- Cells, Cultured, Dexamethasone pharmacology, Dose-Response Relationship, Drug, Gene Expression drug effects, Humans, In Vitro Techniques, Lipopolysaccharides administration & dosage, RNA, Messenger genetics, Interferon-gamma pharmacology, Interleukin-4 pharmacology, Monocytes metabolism, Plasminogen Inactivators metabolism
- Abstract
Using a specific enzyme-linked immunosorbent assay, plasminogen activator inhibitor-2 (PAI-2) was quantitated in cultures of human monocytes. Lipopolysaccharide (LPS) increased both extracellular and cell-associated PAI-2 levels, as well as PAI-2 mRNA measured by Northern analysis. Both the lymphokine, interleukin-4 (IL-4) (greater than or equal to 10 pmol/L), and the glucocorticoid, dexamethasone (100 nmol/L), inhibited PAI-2 formation and PAI-2 mRNA induction. Another lymphokine, interferon-gamma (IFN-gamma) (100 U/mL), as for IL-4 alone, did not stimulate PAI-2 formation; however, in contrast to IL-4, IFN-gamma did not reverse the LPS effect but could potentiate it. The suppression of PAI-2 formation by IL-4 and glucocorticoid in stimulated human monocytes extends the list of monocyte products whose synthesis can be downregulated in these cells by the two agents. The findings could have relevance to the control by monocytes/macrophages of connective tissue resorption, including that of fibrin, at sites of inflammation.
- Published
- 1992